Acceleron Pharma IncChange company Symbol lookupSelect an option...XLRN Acceleron Pharma IncAGNC Agnc Investment CorpACM AECOMCLSN Celsion CorpBAC Bank of America CorpGPHBF Graphene 3D Lab Inc(British Columbia)ITRI Itron IncLTTTX MFS Lifetime 2025 Fund Class R3HLI Houlihan Lokey IncKICK Master Glazier's Karate International IncGo
Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.
|
|
|
|
| |
Upcoming Events
Past Earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
| Date | Event description | Earnings per share actual | Earnings estimate range | Previous year's actual |
|---|---|---|---|---|
| November 5, 2020 | Q3 2020 Earnings Release | -$0.66 | -$0.83 to -$0.01 | -$0.86 |
| August 6, 2020 | Q2 2020 Earnings Release | -$0.34 | -$1.06 to $0.13 | -$0.34 |
| May 11, 2020 | Q1 2020 Earnings Release | -$0.95 | -$1.06 to -$0.57 | -$0.74 |
| February 27, 2020 | Q4 2019 Earnings Release | -$0.44 | -$0.91 to -$0.011 | -- |
Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.
, , , Copyright © 2021. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.